Seeking Alpha

Rosetta Genomics (ROSG +4.8%) gets a lift today after saying earlier that a manuscript on the...

Rosetta Genomics (ROSG +4.8%) gets a lift today after saying earlier that a manuscript on the development and validation of the Company's microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|